We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

108 hedge funds and large institutions have $938M invested in Portola Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more call options, than puts

Call options by funds: $531K | Put options by funds: $222K

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

2% less funds holding

Funds holding: 110108 (-2)

10% less capital invested

Capital invested by funds: $1.05B → $938M (-$110M)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
108
Holders Change
-2
Holders Change %
-1.82%
% of All Funds
3.13%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
14
Increased
39
Reduced
26
Closed
16
Calls
$531K
Puts
$222K
Net Calls
+$309K
Net Calls Change
-$144K
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
76
Paradigm Asset Management
New York
$313K -$1.06M -40,100 -76%
TD Asset Management
77
TD Asset Management
Ontario, Canada
$296K -$140K -5,300 -31%
TC
78
TFS Capital
Pennsylvania
$284K -$1.73M -65,839 -85%
USAA
79
United Services Automobile Association
Texas
$260K
VKH
80
Virtu KCG Holdings
New York
$234K +$244K +9,258 New
UBS AM
81
UBS AM
Illinois
$207K +$29K +1,100 +15%
TC
82
Travelers Companies
Minnesota
$179K +$186K +7,072 New
QT
83
Quantbot Technologies
New York
$178K +$157K +5,956 +541%
Barclays
84
Barclays
United Kingdom
$170K -$123K -4,684 -41%
Legal & General Group
85
Legal & General Group
United Kingdom
$140K +$143K +5,424 New
MCM
86
Manchester Capital Management
Vermont
$128K
Group One Trading
87
Group One Trading
Illinois
$93K -$18.3K -696 -16%
Canada Life
88
Canada Life
Manitoba, Canada
$91K +$94.8K +3,600 New
Bank of America
89
Bank of America
North Carolina
$88K +$90.5K +3,437 +6,610%
CAW
90
Cornerstone Advisors (Washington)
Washington
$83K
U
91
UBS
Switzerland
$80K +$20.3K +771 +32%
BNP Paribas Financial Markets
92
BNP Paribas Financial Markets
France
$55.3K +$56.1K +2,130 +3,610%
JIC
93
Joel Isaacson & Co
New York
$51K
EWM
94
Evercore Wealth Management
New York
$34K
Citigroup
95
Citigroup
New York
$32K -$39.2K -1,489 -54%
Teacher Retirement System of Texas
96
Teacher Retirement System of Texas
Texas
$28K -$817 -31 -3%
BCM
97
Blume Capital Management
California
$25K
BlackRock
98
BlackRock
New York
$21K
WA
99
WFG Advisors
Texas
$11K
ClearBridge Investments
100
ClearBridge Investments
New York
$10K

PTLA Hedge Fund Activity: Q3 2014 in Review

108 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2014, worth a combined $938M — down 10% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PTLA and 14 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 39 added.

The largest buyer was Fidelity Investments, adding an estimated $9.22M. The largest seller was OrbiMed, cutting an estimated $13.5M.

  • 108 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2014, down from 110 in Q2 2014.
  • Funds reported $938M of Portola Pharmaceuticals, Inc. stock for Q3 2014, down 10% quarter-over-quarter.
  • 14 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2014 and 16 closed out, a net change of -2 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2014 was Fidelity Investments, an estimated $9.22M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2014 was OrbiMed, an estimated $13.5M sold.

Based on aggregated 13F filings for Q3 2014.